量研学術機関リポジトリ「QST-Repository」は、国立研究開発法人 量子科学技術研究開発機構に所属する職員等が生み出した学術成果（学会誌発表論文、学会発表、研究開発報告書、特許等）を集積しインターネット上で広く公開するサービスです。 Welcome to QST-Repository where we accumulates and discloses the academic research results(Journal Publications, Conference presentation, Research and Development Report, Patent, etc.) of the members of National Institutes for Quantum Science and Technology.
Thank you very much for using our website. On the 11th of March 2019, this site was moved from our own network server to the JAIRO Cloud network server. If you previously bookmarked this site, that bookmark will no longer work. We would be grateful if you could bookmark the website again. Thank you very much for your understanding and cooperation.
1. Skull Base and Paracervical Tumors
To estimate the toxicity and efficacy of the clinical trials for patients with skull base and paracervical tumors treated with carbon ion radiotherapy.
A phase I/II dose escalation study for skull base and paracervical tumor was initiated in April 1997. The phase I/II dose escalation trial was performed up to the fourth-stage dose level. From April 2004, a phase II clinical trial was initiated under the Highly Advanced Medical Technology scheme with an irradiation schedule of60.8 GyE in 16 fractions over four weeks.
At the time of analysis, there was no evidence of any serious acute or late reactions in skull base and paracervical tumors. For skull base and paracervical tumor, the carbon ion dose in excess of 57.6 GyE improves local control.
2. Head-and-Neck Tumors
To evaluate the efficacy of carbon ion radiotherapy for malignant head-and-neck tumors.
Between April 1997 and August 2009, 363 cases with locally advanced, histologically proven, and new or recurrent malignant tumors of the head-and-neck were treated with carbon ions. Treatment dose was 64.0 GyE in 16 fractions over 4 weeks (or 57.6 GyE when a wide area of skin was included in the target volume).
There were no acute reactions worse than grade 3 and no late toxicities worse than grade 2. The five-year local control and overall survival rates were 73% and 53%, respectively. But the five- year local control rate was 24% for bone and soft tissue sarcomas, and the five-year overall survival rate was 37% for malignant melanomas.
Carbon ion radiotherapy for malignant head-and-neck tumors can be described as presenting no clinical problems. Although local control of carbon ion radiotherapy was promising for malignant head-and-neck tumor excluding sarcoma, the survival rate was not commensurate with the favorable local control rate of malignant melanoma. On the basis of the results of the analysis, this part of the study was divided into two additional protocols, one for bone and soft tissue sarcomas and another for mucosal malignant melanomas.
Carbon Ion Radiotherapy for Skull Base and Head-and-Neck Tumors
